WO2001077685A3 - Diagnosis and treatment of gastrointestinal disease - Google Patents

Diagnosis and treatment of gastrointestinal disease Download PDF

Info

Publication number
WO2001077685A3
WO2001077685A3 PCT/US2001/010259 US0110259W WO0177685A3 WO 2001077685 A3 WO2001077685 A3 WO 2001077685A3 US 0110259 W US0110259 W US 0110259W WO 0177685 A3 WO0177685 A3 WO 0177685A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
gastrointestinal disease
methods
relates
Prior art date
Application number
PCT/US2001/010259
Other languages
French (fr)
Other versions
WO2001077685A2 (en
Inventor
C Timothy Wang
Original Assignee
Gen Hospital Corp
C Timothy Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, C Timothy Wang filed Critical Gen Hospital Corp
Priority to AU2001253024A priority Critical patent/AU2001253024A1/en
Priority to CA002404852A priority patent/CA2404852A1/en
Publication of WO2001077685A2 publication Critical patent/WO2001077685A2/en
Publication of WO2001077685A3 publication Critical patent/WO2001077685A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to methods for the diagnosis and treatment of gastrointestinal disease. More specifically, the invention relates to methods for the diagnosis and treatment of duodenal ulcer disease and gastric atrophy.
PCT/US2001/010259 2000-04-10 2001-03-30 Diagnosis and treatment of gastrointestinal disease WO2001077685A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001253024A AU2001253024A1 (en) 2000-04-10 2001-03-30 Diagnosis and treatment of gastrointestinal disease
CA002404852A CA2404852A1 (en) 2000-04-10 2001-03-30 Diagnosis and treatment of gastrointestinal disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19591400P 2000-04-10 2000-04-10
US60/195,914 2000-04-10

Publications (2)

Publication Number Publication Date
WO2001077685A2 WO2001077685A2 (en) 2001-10-18
WO2001077685A3 true WO2001077685A3 (en) 2002-07-25

Family

ID=22723338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010259 WO2001077685A2 (en) 2000-04-10 2001-03-30 Diagnosis and treatment of gastrointestinal disease

Country Status (3)

Country Link
AU (1) AU2001253024A1 (en)
CA (1) CA2404852A1 (en)
WO (1) WO2001077685A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
FI119572B (en) * 2004-03-05 2008-12-31 Biohit Oyj A method for predicting gastric mucosa
DK3071206T3 (en) 2013-11-22 2021-05-25 CL BioSciences LLC GASTRINE ANTAGONISTS (EG YF476, NETAZEPID) FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO1996015456A1 (en) * 1994-11-16 1996-05-23 Locus Genex Oy Method for screening the risk of gastric cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO1996015456A1 (en) * 1994-11-16 1996-05-23 Locus Genex Oy Method for screening the risk of gastric cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AZUMA T ET AL: "CARBOXYL TERMINAL GLYCINE EXTENDED PROGASTRIN GASTRIN-G IN GASTRIC ANTRAL MUCOSA OF PATIENTS WITH GASTRIC OR DUODENAL ULCER AND IN GASTRINOMAS", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 5, no. 5, 1990, pages 525 - 529, XP001053155, ISSN: 0815-9319 *
BARDRAM L: "PROGASTRIN IN SERUM FROM ZOLLINGER-ELLISON PATIENTS AN INDICATOR OF MALIGNANCY", GASTROENTEROLOGY, vol. 98, no. 6, 1990, pages 1420 - 1426, XP001053157, ISSN: 0016-5085 *
DEERING T B ET AL: "COMPARISON OF AN H-2 RECEPTOR ANTAGONIST AND A NEUTRALIZING ANTI ACID ON POST PRANDIAL ACID DELIVERY INTO THE DUODENUM IN PATIENTS WITH DUODENAL ULCER", GASTROENTEROLOGY, vol. 73, no. 1, 1977, pages 11 - 14, XP001053154, ISSN: 0016-5085 *
DING XI-QIN ET AL: "Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: A study of their effects on rat stomach enterochromaffin-like cell activity.", PHARMACOLOGY & TOXICOLOGY, vol. 81, no. 5, 1997, pages 232 - 237, XP001053140, ISSN: 0901-9928 *
PENDLEY CHARLES E ET AL: "RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 273, no. 3, 1995, pages 1015 - 1022, XP001053151, ISSN: 0022-3565 *
SINGH POMILA ET AL: "Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM.", AMERICAN JOURNAL OF PHYSIOLOGY., vol. 278, no. 3 part 1, March 2000 (2000-03-01), pages G390 - G399, XP001053152, ISSN: 0002-9513 *
SINGH POMILA ET AL: "Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen.", GASTROENTEROLOGY, vol. 119, no. 1, July 2000 (2000-07-01), pages 162 - 171, XP001053110, ISSN: 0016-5085 *
SWAN S K ET AL: "Review article: The pharmacokinetics of rabeprazole in health and disease.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 13, no. SUPPL. 3, August 1999 (1999-08-01), pages 11 - 17, XP001053149, ISSN: 0269-2813 *
VAN SOLINGE W W ET AL: "RADIOIMMUNOASSAY FOR SEQUENCE 38-54 OF HUMAN PROGASTRIN INCREASED DIAGNOSTIC SPECIFICITY OF GASTRIN-CELL DISEASES", CLINICA CHIMICA ACTA, vol. 192, no. 1, 1990, pages 35 - 46, XP001053147, ISSN: 0009-8981 *
WANG TIMOTHY C ET AL: "Processing and proliferative effects of human progastrin in transgenic mice.", JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 8, 1996, pages 1918 - 1929, XP001053111, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2001077685A2 (en) 2001-10-18
CA2404852A1 (en) 2001-10-18
AU2001253024A1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
AU2002344736A1 (en) Gastrointestinal tract treatment apparatus
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
MXPA03007983A (en) Process for the preparation of middle distillates.
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
EP1408820A4 (en) Capsule and method for treating or diagnosing the intestinal tract
AU2003219211A1 (en) Gastric ring for the treatment of obesity
HK1068335A1 (en) Novel arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
HK1047086A1 (en) Method for the preparation of citalopram.
ZA200206699B (en) Method for the preparation of citalopram.
AU2000276362A1 (en) Composition for the treatment of diabetes
ZA200309471B (en) Method for the preparation of escitalopram.
AU2002363168A1 (en) Heat-resistant filter layer, filter body and method for the production thereof
WO2001072754A8 (en) Alkylated imidazopyridine derivatives
ZA200403432B (en) Method for the preparation of escitalopram.
DK1455794T3 (en) CIC-2 channel opener for the treatment of gastric or intestinal ulcer
AU2002358199A1 (en) Shorts or underpants retaining the sexual organs
AU2002217316A1 (en) Use of terpenes for the treatment of digestive tract infections
WO2002051855A3 (en) Motilide compounds
WO2001077685A3 (en) Diagnosis and treatment of gastrointestinal disease
AU2002236781A1 (en) Treatment for snoring
MXPA02006102A (en) Process for the preparation of bromodifluoroacetic compounds.
AU2001292705A1 (en) Method of treating gastrointestinal disorders, particularly colitis
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
ZA200101058B (en) Process for the treatment of gases.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2404852

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10257169

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP